Research Collaboration Targets Solid Tumors with CAR-T Cells
Imugene Ltd, a clinical stage immuno-oncology company and Celularity Inc., a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic therapies, have entered into an exclusive research collaboration. As part of the partnership, Imugene and Celularity will initially collaborate to develop the combination of Imugene’s CD19 oncolytic virus technology and Celularity’s CD19 targeting allogeneic chimeric antigen receptor (CAR) T cellular therapy, CYCART-19, for the treatment of solid tumors. Robert J. Hariri, M.D., Ph.D., founder, Chairperson and Chief Executive Officer of Celularity, said, “We are excited to initiate this research collaboration, which we believe will lay the foundation for a new approach to the treatment of solid tumors. Most solid tumors have variable targetable antigens, limiting CAR-T cell therapy efficacy. The treatment strategy we are targeting with Imugene has the potential to apply to a range of indications and allow cellular medicine to overcome obstacles that have prevented its use in a broad range of cancers. The Imugene approach, which leads to uniform expression of CD19 in solid tumors combined with CD19 CAR-T cells, has the potential to improve patient outcomes.”
Read more about the new partnership here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
